SGEN stock forecast
Our latest prediction for Seagen Inc's stock price was made on the Nov. 15, 2023 when the stock price was at 212.07$.
In the short term (2weeks), SGEN's stock price should underperform the market by -2.26%. During that period the price should oscillate between -6.16% and +0.13%.
In the medium term (3months), SGEN's stock price should underperform the market by -9.32%. During that period the price should oscillate between -26.09% and +5.33%.Get email alerts
Create a solid portfolio with SGEN
About Seagen Inc
seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys
At the moment the company generates 140M USD in revenues.
On its last earning announcement, the company reported a loss of -4.01$ per share.
The book value per share is 8.69$
Three months stock forecastNov. 15, 2023
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|